- A Case of Late Onset-Acute Tubulointerstitial Nephritis with Infliximab and Mesalazine Treatment in a Patient with Crohn's Disease
-
Yoo YJ, Chung SY, Gu DH, Ko GJ, Pyo HJ, Kwon YJ, Bak YT, Won NH
- KMID: 2155329
- Korean J Gastroenterol.
- 2014 May;63(5):308-312.
- doi: 10.4166/kjg.2014.63.5.308
Infliximab is a chimeric anti-tumor necrosis factor-alpha monoclonal antibody. Infusion related reactions and infection are well known side effects of infliximab; however, renal complications have not been well recognized. We... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
-
Kim ES, Kim KO, Jang BI, Lee CK, Kim HJ, Lee KM, Kim YS, Eun CS, Jung SA, Yang SK, Lee J, Kim TO, Jung Y, Seo GS, Yoon SM, the IBD Study Group of the Korean Association for the Study of the Intestinal Diseases (KASID)
- KMID: 2411966
- Gut Liver.
- 2016 May;10(3):391-398.
- doi: 10.5009/gnl15126
BACKGROUND/AIMS: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn's disease (CD)... -
- CITED
-
- Close
- SHARE
-
- Close
